Marinus Pharmaceuticals (NASDAQ:MRNS) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued to investors on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ MRNS opened at $0.55 on Wednesday. The stock has a market capitalization of $30.32 million, a PE ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a one year low of $0.22 and a one year high of $9.07. The business’s fifty day moving average price is $0.55 and its 200-day moving average price is $0.72.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in shares of Marinus Pharmaceuticals during the fourth quarter worth $36,000. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new stake in Marinus Pharmaceuticals during the 4th quarter worth about $54,000. World Investment Advisors LLC bought a new position in Marinus Pharmaceuticals in the 3rd quarter worth about $104,000. Deltec Asset Management LLC bought a new position in Marinus Pharmaceuticals in the 4th quarter worth about $107,000. Finally, XTX Topco Ltd grew its holdings in Marinus Pharmaceuticals by 1,564.7% during the 4th quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 206,614 shares in the last quarter. 98.80% of the stock is currently owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.